ATOS

Atossa Therapeutics Inc

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for...

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen Atossa Therapeutics Announces Issuance of...

Ascendiant Capital Markets lifted their price objective on Atossa Genetics from $7.75 to $8.00 and gave the company a "buy" rating in a report on Monday...

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across...

Shares of Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) have been assigned an average rating of "Hold" from the five analysts that are covering the company, Marketbeat.com reports. Two...

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma Insilico Medicine and...

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation Atossa...

Atossa Genetics (NASDAQ:ATOS - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07...

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update PR...